Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc.,…
Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a…
Aurora Spine Launches New Biologics Portfolio
New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integrated Source…
NeXtGen Biologics Announces Issuance Of A Third New Patent Covering Axolotl-Derived Technology
GAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating…
